Vertex Pharma's Telaprevir Improves Viral Cure Rates In Hepatitis C
Wednesday, April 6, 2011 at 4:18PM Vertex Pharmaceuticals said Thursday its Telaprevir-based therapy significantly improved viral cure rates in hepatitis C patients whose prior treatment with pegylated-interferon and ribavirin was unsuccessful. Vertex announced final results from its phase 3 Realize study pertaining to Telaprevir.
The Realize study group consisted of patients who either relapsed, had a partial response or had a null response.
Patients were randomised to two telaprevir-based treatment arms, simultaneous or lead-in, or a control arm of 48 weeks of pegylated-interferon or PEG and RBV together are the currently approved medicines for genotype 1 hepatitis C.
For those in the simultaneous start arm, 12 weeks of telaprevir in combination with PEG and RBV was followed by an additional 36 weeks of pegylated-interferon and ribavirin alone. In the control arm, 12 weeks of placebo, PEG and RBV, were followed by 36 weeks of PEG and RBV alone.
To view full article CLICK HERE
Reader Comments